Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.

This episode includes insights from around the biopharma world for the business week ended 15 January 2021.

This week, we take a look some of the major news to come out of the J.P. Morgan Healthcare Conference, a big oncology deal for one Chinese company, lessons in Alzheimer's development, and a pipeline update from one large German firm. 

These and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Play, SoundCloud and TuneIn - and also now on Spotify Podcasts - and also via smart speakers if one of these channels has been set up as your default podcast provider. 

Stories mentioned in this episode:

(Also see "J.P. Morgan Day 1: Companies Make Deal-Making, COVID-19 Promises" - Scrip, 11 Jan, 2021.)

(Also see "J.P. Morgan Day 2: Pharma Offers (Some) Views On Drug Pricing Reform" - Scrip, 12 Jan, 2021.)

(Also see "BeiGene Ties Up With Novartis To Take PD-1 Global In $2.2bn+ Deal" - Scrip, 12 Jan, 2021.)

(Also see "An Alzheimer’s Win: How Lilly Designed Donanemab Trial To Succeed" - Scrip, 12 Jan, 2021.)

(Also see "Bayer Puts Spotlight On Pharma Pipeline" - Scrip, 13 Jan, 2021.)


Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts